Tech Center 1600 • Art Units: 1649 1675
This examiner grants 37% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16649525 | AFFINITY-TAGGED PHOTOSWITCHES AND METHODS OF USE THEREOF | Final Rejection | The Regents of the University of California |
| 17992403 | Agents, Uses and Methods for the Treatment of Synucleinopathy | Final Rejection | H. Lundbeck A/S |
| 17914817 | Uses of Tau Phosphosites as Biomarkers for Alzheimer's Disease | Non-Final OA | Washington University |
| 17640627 | COMPOSITIONS AND METHODS FOR USING SILK-ELASTINLIKE PROTEIN-BASED POLYMERS | Non-Final OA | University of Utah Research Foundation |
| 18004479 | Biomarkers for Identifying Relapses in Multiple Sclerosis | Non-Final OA | The Board of Regents of the University of Oklahoma |
| 17509910 | Methods of Safe Administration of Anti-Tau Antibody | Final Rejection | JANSSEN PHARMACEUTICA NV |
| 18360222 | Modified anti-PD-L1 Antibody and Methods and Uses for Treating a Neurodegenerative Disease | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 18054457 | ANTIBODIES FOR THE TREATMENT OF SYNUCLEINOPATHIES AND NEUROINFLAMMATION | Final Rejection | MOR RESEARCH APPLICATIONS LTD. |
| 18147420 | METHODS AND SYSTEMS OF DIAGNOSING BRAIN INJURY | Non-Final OA | Abbott Laboratories |
| 17742050 | Activity Modulator | Non-Final OA | University of Tsukuba |
| 17820815 | DIAGNOSTIC BIOMARKERS FOR DETECTING, SUBTYPING, AND/OR ASSESSING PROGRESSION OF MULTIPLE SCLEROSIS | Non-Final OA | Rowan University |
| 17051857 | DETECTION OF AUTOANTIBODIES AGAINST DEIMINATED PROTEIN EPITOPES ASSOCIATED WITH BRAIN OXYGEN DEPRIVATION | Final Rejection | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. |
| 16344298 | GENE TRANSFER COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEGENERATIVE DISEASES | Final Rejection | The Children's Hospital of Philadelphia |
| 18354403 | PSILOCYBIN COMPOSITIONS | Non-Final OA | TURTLE BEAR HOLDINGS, LLC |
| 18114381 | PSILOCYBIN COMPOSITIONS | Non-Final OA | TURTLE BEAR HOLDINGS, LLC |
| 18145767 | Collagen Type XVIII Assay | Non-Final OA | Nordic Bioscience A/S |
| 18279715 | HUMANIZED ANTIBODIES AGAINST IRHOM2 | Non-Final OA | New YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HO |
| 18456972 | ANTI-THYMOCYTE GLOBULIN | Non-Final OA | SAB, LLC |
| 18271804 | ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF | Non-Final OA | Starmob Biologics (Shanghai) Co., Ltd. |
| 18260725 | ANTIBODY SPECIFICALLY BINDING TO CD47 AND ANTIGEN-BINDING FRAGMENT THEREOF | Non-Final OA | BEIJING HANMI PHARMACEUTICAL CO., LTD. |
| 17818481 | NEW TAU SPECIES | Final Rejection | ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS |
| 18333797 | HUMAN NEUREGULIN-1 (NRG-1) RECOMBINANT FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Salubris (Chengdu) Biotech Co., Ltd. |
| 18265617 | OPTIC NERVE PROTECTING AGENT CONTAINING ANTI-LRP1 ANTIBODY | Non-Final OA | NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION |
| 17764819 | PROTEIN BINDERS TO IRHOM2 EPITOPES | Non-Final OA | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL |
| 14346822 | STIMULUS-ELICITED GENOMIC PROFILE MARKERS OF A NEURODEGENERATIVE CONDITION | Non-Final OA | West Virginia University |
| 18178055 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | Non-Final OA | Immatics Biotechnologies GmbH |
| 17925981 | METHOD FOR DETECTING A ß-SHEET AGGREGATE FORM OF A PROTEIN FORMING ß-SHEET AGGREGATES | Non-Final OA | CISBIO BIOASSAYS |
| 18188707 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFLAMMATION | Non-Final OA | RSEM, LIMITED PARTNERSHIP |
| 17783143 | Compounds for treatment of eye diseases | Final Rejection | Region Midtjylland |
| 18155230 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES | Final Rejection | Pinteon Therapeutics Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy